Panacea Biotec Ltd Stock Price Today (NSE: PANACEABIO)
Fundamental Score
Panacea Biotec Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Panacea Biotec Ltd share price today is ₹362.25, up +0.00% on NSE/BSE as of 17 February 2026. Panacea Biotec Ltd (PANACEABIO) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.23K (Cr). The 52-week high for PANACEABIO share price is ₹N/A and the 52-week low is ₹N/A. The company has a Return on Equity (ROE) of -4.92% and a debt-to-equity ratio of 0.03.
Panacea Biotec Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Panacea Biotec Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Panacea Biotec Share Price: A Conservative Investor's Perspective
The pharmaceutical industry, while offering potential for significant growth, demands rigorous due diligence. Unlike other sectors, pharmaceutical companies face unique risks related to regulatory approvals, patent expirations, and the constant need for innovation. This analysis examines the current state of Panacea Biotec share price, specifically from the viewpoint of a conservative value investor prioritizing capital safety and long-term sustainability. This is a part of a larger 80-parameter fundamental audit verified by Sweta Mishra.
Currently, Panacea Biotec’s financials present some concerns for a value-oriented investor. The absence of a Price-to-Earnings (PE) ratio suggests either negative earnings or inconsistent profitability. A more significant red flag is the Return on Capital Employed (ROCE) of -4.57%. This negative ROCE indicates that the company is currently destroying value, rather than creating it. This directly impacts the company's moat because a negative ROCE makes it difficult for the company to reinvest in its operations, research and development, or other initiatives that would strengthen its competitive position. A strong moat is crucial for sustainable long-term returns.
A critical aspect of value investing is understanding the quality of management and their capital allocation decisions. When we consider
Mankind Pharma Ltd, we observe a company that has historically demonstrated a more consistent track record of profitability and capital efficiency. This suggests potentially stronger management and a better ability to navigate the complexities of the pharmaceutical industry. While comparisons with sector peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd are also important, a thorough assessment of management competence remains paramount.For a conservative investor, the negative ROCE and the lack of a PE ratio are significant concerns. While the pharmaceutical sector can offer opportunities, the current financial data for Panacea Biotec suggests a high level of risk. Further investigation into the company's balance sheet, cash flow statements, and future growth prospects is necessary to determine if the potential upside outweighs the inherent risks. As value investors, we emphasize understanding the underlying business and only investing when we have a high degree of confidence in the long-term sustainability of the investment.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Panacea Biotec Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PANACEABIO across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (72.48%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (-4.92%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-4.57%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-2.59%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-905.95%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (0.55% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (-9.49x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-603.42 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 2.86%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Panacea Biotec Ltd Financial Statements
Comprehensive financial data for Panacea Biotec Ltd including income statement, balance sheet and cash flow
About PANACEABIO (Panacea Biotec Ltd)
Panacea Biotec Ltd (PANACEABIO) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹2.23K (Cr). Panacea Biotec Ltd has delivered a Return on Equity (ROE) of -4.92% and a ROCE of -4.57%. The debt-to-equity ratio stands at 0.03, reflecting the company's capital structure. Investors tracking PANACEABIO share price can monitor key metrics including P/E ratio, promoter holding of 72.48%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
PANACEABIO Share Price: Frequently Asked Questions
What is the current share price of Panacea Biotec Ltd (PANACEABIO)?
As of 17 Feb 2026, 10:18 am IST, Panacea Biotec Ltd share price is ₹362.25. The PANACEABIO stock has a market capitalisation of ₹2.23K (Cr) on NSE/BSE.
Is PANACEABIO share price Overvalued or Undervalued?
PANACEABIO share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Panacea Biotec Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of PANACEABIO share price?
The 52-week high of PANACEABIO share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Panacea Biotec Ltd share price?
Key factors influencing PANACEABIO share price include quarterly earnings growth (Sales Growth: -4.22%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Panacea Biotec Ltd a good stock for long-term investment?
Panacea Biotec Ltd shows a 5-year Profit Growth of 11.74% and an ROE of -4.92%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.03 before investing in PANACEABIO shares.
How does Panacea Biotec Ltd compare with its industry peers?
Panacea Biotec Ltd competes with major peers in the Pharmaceuticals. Investors should compare PANACEABIO share price P/E of 0.00x and ROE of -4.92% against the industry averages to determine competitive standing.
What is the P/E ratio of PANACEABIO and what does it mean?
PANACEABIO share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is PANACEABIO performing according to Bull Run's analysis?
PANACEABIO has a Bull Run fundamental score of 15.3/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does PANACEABIO belong to?
PANACEABIO operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Panacea Biotec Ltd share price.
What is Return on Equity (ROE) and why is it important for PANACEABIO?
PANACEABIO has an ROE of -4.92%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Panacea Biotec Ltd generates profits from shareholders capital.
How is PANACEABIO debt-to-equity ratio and what does it indicate?
PANACEABIO has a debt-to-equity ratio of 0.03, which indicates conservative financing with low financial risk.
What is PANACEABIO dividend yield and is it a good dividend stock?
PANACEABIO offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Panacea Biotec Ltd shares.
How has PANACEABIO share price grown over the past 5 years?
PANACEABIO has achieved 5-year growth rates of: Sales Growth 0.55%, Profit Growth 11.74%, and EPS Growth 11.74%.
What is the promoter holding in PANACEABIO and why does it matter?
Promoters hold 72.48% of PANACEABIO shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Panacea Biotec Ltd.
What is PANACEABIO market capitalisation category?
PANACEABIO has a market capitalisation of ₹2230 crores, placing it in the Small-cap category.
How volatile is PANACEABIO stock?
PANACEABIO has a beta of N/A. A beta > 1 suggests the Panacea Biotec Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is PANACEABIO operating profit margin trend?
PANACEABIO has a 5-year average Operating Profit Margin (OPM) of -2.59%, indicating the company's operational efficiency.
How is PANACEABIO quarterly performance?
Recent quarterly performance shows Panacea Biotec Ltd YoY Sales Growth of -4.22% and YoY Profit Growth of -905.95%.
What is the institutional holding pattern in PANACEABIO?
PANACEABIO has FII holding of 1.06% and DII holding of 1.80%. Significant institutional holding often suggests professional confidence in the Panacea Biotec Ltd stock.